Kolon Life Science Inc
KOSDAQ:102940
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
22 050
61 400
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| KR |
K
|
Kolon Life Science Inc
KOSDAQ:102940
|
762.8B KRW |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
964.8B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.9B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
268.4B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
209.9B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
219B CHF |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.7T DKK |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
267.4B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
149.5B USD |
Loading...
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
94.6B EUR |
Loading...
|
Market Distribution
| Min | -168 471.3% |
| 30th Percentile | -2.9% |
| Median | 1.9% |
| 70th Percentile | 5.8% |
| Max | 21 012.5% |
Other Profitability Ratios
Kolon Life Science Inc
Glance View
KOLON Life Science, Inc. engages in the manufacture and sale of pharmaceuticals and environment materials. The company is headquartered in Seoul, Seoul and currently employs 451 full-time employees. The company went IPO on 2009-04-07. The firm operates its business under two segments. The Chemical Business segment produces and sells raw drug products, which are the raw materials of new drugs and generic drugs, antibacterial agents that suppress bacterial growth, water treatment agents for environmental purification, and functional material products for cosmetics. The Bio Business segment manufactures and sells bio new medicines based on cell gene therapy products.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Kolon Life Science Inc is 8.4%, which is above its 3-year median of -24.5%.
Over the last 3 years, Kolon Life Science Inc’s Net Margin has increased from -3% to 8.4%. During this period, it reached a low of -60.7% on Sep 30, 2024 and a high of 8.4% on Oct 30, 2025.